Effects of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials-Reference-Cited by-同舟云学术

Effects of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials

Published:2020-09-04 Issue:12 Volume:22 Page:2487-2492
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Verma Subodh¹^ORCID,McGuire Darren K.²,Bain Stephen C.³^ORCID,Bhatt Deepak L.⁴,Leiter Lawrence A.¹,Mazer C. David¹,Monk Fries Tea⁵,Pratley Richard E.⁶,Rasmussen Søren⁵,Vrazic Hrvoje⁵,Zinman Bernard⁷^ORCID,Buse John B.⁸

Affiliation:

1. Li Ka Shing Knowledge Institute, St. Michael's Hospital and University of Toronto Toronto Ontario Canada

2. Division of Cardiology University of Texas Southwestern Medical Center Dallas Texas USA

3. Institute of Life Science, Swansea University Swansea UK

4. Brigham and Women's Hospital Heart and Vascular Center & Harvard Medical School Boston Massachusetts USA

5. Novo Nordisk A/S Søborg Denmark

6. AdventHealth Translational Research Institute Orlando Florida USA

7. Lunenfeld–Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto Toronto Ontario Canada

8. University of North Carolina School of Medicine Chapel Hill North Carolina USA

Funder

Novo Nordisk

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14160

Reference18 articles.

1. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020

2. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020

3. Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus

4. Clinical Effectiveness of Liraglutide Across Body Mass Index in Patients with Type 2 Diabetes in the United States: A Retrospective Cohort Study

5. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beyond weight loss: the potential of glucagon-like peptide-1 receptor agonists for treating heart failure with preserved ejection fraction;Heart Failure Reviews;2024-09-13

2. Use of continuous glucose monitoring when initiating glucagon‐like peptide‐1 receptor agonist therapy in insulin‐treated diabetes;Diabetes, Obesity and Metabolism;2024-08-28

3. The Kidney in Obesity: Current Evidence, Perspectives and Controversies;Current Obesity Reports;2024-08-14

4. Cardio‐Renal‐Metabolic Outcomes Associated With the Use of GLP‐1 Receptor Agonists After Heart Transplantation;Clinical Transplantation;2024-07

5. GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage;American Journal of Physiology-Heart and Circulatory Physiology;2024-05-01